See more : Styland Holdings Limited (0211.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Shin Poong Pharm.Co.,Ltd. (019175.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shin Poong Pharm.Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Biotron Limited (BIT.AX) Income Statement Analysis – Financial Results
- Zix Corporation (ZIXI) Income Statement Analysis – Financial Results
- HIROSHIMA GAS Co.,Ltd. (9535.T) Income Statement Analysis – Financial Results
- ASSA ABLOY AB (publ) (ASSA-B.ST) Income Statement Analysis – Financial Results
- LG Innotek Co., Ltd. (011070.KS) Income Statement Analysis – Financial Results
Shin Poong Pharm.Co.,Ltd. (019175.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://shinpoong.co.kr
About Shin Poong Pharm.Co.,Ltd.
Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.23B | 209.29B | 189.24B | 197.75B | 189.72B | 187.39B | 185.00B | 194.15B | 195.95B | 220.29B | 215.96B | 221.17B | 229.69B | 232.06B | 217.26B | 188.14B | 165.92B |
| Cost of Revenue | 119.95B | 131.31B | 111.85B | 121.22B | 113.54B | 111.50B | 104.88B | 106.22B | 109.27B | 119.33B | 120.45B | 131.78B | 126.56B | 121.33B | 112.11B | 92.31B | 86.02B |
| Gross Profit | 80.28B | 77.97B | 77.39B | 76.53B | 76.18B | 75.89B | 80.12B | 87.93B | 86.69B | 100.96B | 95.51B | 89.39B | 103.14B | 110.73B | 105.15B | 95.83B | 79.90B |
| Gross Profit Ratio | 40.09% | 37.26% | 40.89% | 38.70% | 40.16% | 40.50% | 43.31% | 45.29% | 44.24% | 45.83% | 44.23% | 40.42% | 44.90% | 47.72% | 48.40% | 50.94% | 48.15% |
| Research & Development | 56.02B | 30.38B | 17.33B | 5.62B | 5.97B | 4.87B | 4.63B | 6.39B | 9.14B | 5.75B | 3.59B | 6.27B | 4.82B | 5.09B | 45.02M | 656.60M | 867.64M |
| General & Administrative | 7.59B | 111.99B | 5.96B | 5.49B | 5.30B | 5.19B | 5.31B | 6.24B | 6.43B | 4.57B | 5.83B | 6.79B | 6.66B | 11.58B | 11.04B | 14.48B | 12.06B |
| Selling & Marketing | 29.28B | 28.36B | 24.00B | 21.91B | 20.80B | 18.95B | 21.62B | 22.31B | 20.36B | 20.35B | 18.06B | 16.77B | 17.02B | 14.97B | 24.02B | 21.62B | 18.59B |
| SG&A | 71.58B | 111.99B | 29.95B | 27.41B | 26.09B | 24.13B | 26.93B | 28.55B | 26.79B | 24.92B | 23.90B | 23.56B | 23.69B | 26.55B | 35.07B | 36.10B | 30.65B |
| Other Expenses | 0.00 | -30.38B | 44.41B | 35.65B | 38.52B | 39.13B | 186.71M | -10.49B | 204.31M | -29.76M | 459.09M | -293.76M | 127.03M | -886.11M | -569.62M | -583.76M | -116.06M |
| Operating Expenses | 127.60B | 111.99B | 91.69B | 68.68B | 70.58B | 68.13B | 72.31B | 78.36B | 82.45B | 81.71B | 70.70B | 65.15B | 64.83B | 66.76B | 69.88B | 64.59B | 60.72B |
| Cost & Expenses | 247.62B | 131.31B | 203.54B | 189.91B | 184.12B | 179.64B | 177.18B | 184.58B | 191.71B | 201.04B | 191.15B | 196.94B | 191.39B | 188.09B | 181.99B | 156.90B | 146.74B |
| Interest Income | 1.17B | 1.03B | 1.88B | 1.93B | 1.51B | 986.76M | 486.25M | 501.06M | 47.32M | 125.38M | 80.94M | 62.20M | 118.87M | 180.19M | 125.49M | 95.42M | 92.13M |
| Interest Expense | 1.72B | 830.99M | 202.06M | 2.94B | 4.11B | 4.28B | 4.48B | 5.36B | 6.54B | 7.58B | 7.54B | 7.80B | 8.35B | 6.93B | 6.25B | 5.68B | 4.13B |
| Depreciation & Amortization | 11.91B | 12.80B | 12.68B | 12.28B | 12.33B | 11.37B | 9.84B | 10.02B | 12.46B | 12.35B | 11.58B | 7.87B | 7.77B | 7.01B | 7.01B | 6.22B | 6.11B |
| EBITDA | -39.81B | -22.22B | 1.27B | 21.04B | 22.87B | 19.12B | 17.99B | 10.32B | 19.49B | 32.31B | 36.39B | 32.05B | 46.01B | 52.29B | 44.07B | 32.33B | 25.70B |
| EBITDA Ratio | -19.88% | 37.26% | 1.92% | 11.91% | 10.93% | 11.77% | 9.85% | 4.69% | 9.52% | 15.38% | 17.96% | 15.25% | 20.73% | 22.53% | 20.19% | 18.50% | 15.55% |
| Operating Income | -47.39B | -34.02B | -9.04B | 11.35B | 8.42B | 10.69B | 7.81B | 9.57B | 4.24B | 19.25B | 24.81B | 24.23B | 38.30B | 43.97B | 35.27B | 31.24B | 19.18B |
| Operating Income Ratio | -23.67% | -16.25% | -4.78% | 5.74% | 4.44% | 5.70% | 4.22% | 4.93% | 2.16% | 8.74% | 11.49% | 10.96% | 16.67% | 18.95% | 16.23% | 16.60% | 11.56% |
| Total Other Income/Expenses | -6.05B | -762.85M | -720.04M | -3.01B | -1.31B | -4.07B | -6.11B | -14.62B | -2.35B | -5.75B | -5.14B | -6.18B | -6.80B | -5.63B | -4.46B | -10.80B | -3.72B |
| Income Before Tax | -53.44B | -34.78B | -8.99B | 8.34B | 7.12B | 5.18B | 1.70B | -3.70B | 2.17B | 13.51B | 19.67B | 18.05B | 31.49B | 38.34B | 30.81B | 20.43B | 15.46B |
| Income Before Tax Ratio | -26.69% | -16.62% | -4.75% | 4.22% | 3.75% | 2.77% | 0.92% | -1.91% | 1.11% | 6.13% | 9.11% | 8.16% | 13.71% | 16.52% | 14.18% | 10.86% | 9.32% |
| Income Tax Expense | 3.83B | 527.29M | 2.54B | 3.29B | 1.72B | 2.37B | 780.74M | 14.90B | 688.80M | 10.15B | 14.19B | 3.72B | 6.63B | 16.59B | 9.72B | 8.34B | 6.62B |
| Net Income | -57.33B | -35.31B | -11.53B | 5.00B | 5.32B | 2.80B | 904.89M | -18.59B | 1.48B | 3.35B | 5.44B | 14.38B | 24.87B | 21.73B | 21.05B | 12.05B | 8.84B |
| Net Income Ratio | -28.63% | -16.87% | -6.09% | 2.53% | 2.81% | 1.50% | 0.49% | -9.58% | 0.75% | 1.52% | 2.52% | 6.50% | 10.83% | 9.37% | 9.69% | 6.41% | 5.33% |
| EPS | -1.12K | -688.79 | -224.84 | 99.40 | 106.53 | 56.00 | 25.00 | -392.02 | 35.00 | 99.00 | 133.65 | 353.18 | 611.62 | 530.57 | 498.93 | 285.23 | 209.13 |
| EPS Diluted | -1.12K | -688.79 | -224.84 | 99.40 | 106.53 | 56.00 | 25.00 | -392.02 | 35.00 | 99.00 | 133.65 | 353.18 | 611.62 | 530.57 | 498.93 | 285.23 | 209.13 |
| Weighted Avg Shares Out | 51.23M | 51.26M | 51.26M | 50.33M | 49.97M | 50.07M | 49.58M | 47.43M | 34.10M | 40.99M | 40.68M | 40.71M | 38.35M | 40.96M | 42.20M | 42.25M | 42.29M |
| Weighted Avg Shares Out (Dil) | 51.26M | 51.26M | 51.26M | 50.33M | 49.97M | 50.07M | 49.58M | 47.43M | 34.10M | 40.99M | 40.68M | 40.71M | 38.35M | 40.96M | 42.20M | 42.25M | 42.29M |
Source: https://incomestatements.info
Category: Stock Reports